Alzheimer Dementia (ad) Clinical Trials
2 recruiting trials for Alzheimer Dementia (ad). Eligibility criteria explained in plain English.
TrialFinderData lists 2 Alzheimer Dementia (ad) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Sunnybrook Health Sciences Centre (1), Universitaire Ziekenhuizen KU Leuven (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is intermittent theta burst stimulation (iTBS) (device, 1 trial), followed by Methylphenidate (MPH), UHR PET/CT scan of the brain with ¹⁸F-FDG.
Track Alzheimer Dementia (ad) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia
This study evaluates whether the combined treatment of methylphenidate and non-invasive brain stimulation, called intermittent theta burst stimulation, can effectively treat...
Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Alzheimer Dementia (ad), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Alzheimer Dementia (ad), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Alzheimer Dementia (ad), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.